AR083541A1 - Derivado de 23-ino-vitamina d - Google Patents

Derivado de 23-ino-vitamina d

Info

Publication number
AR083541A1
AR083541A1 ARP110103926A ARP110103926A AR083541A1 AR 083541 A1 AR083541 A1 AR 083541A1 AR P110103926 A ARP110103926 A AR P110103926A AR P110103926 A ARP110103926 A AR P110103926A AR 083541 A1 AR083541 A1 AR 083541A1
Authority
AR
Argentina
Prior art keywords
alkyl group
vitamin
group
alkyl
ino
Prior art date
Application number
ARP110103926A
Other languages
English (en)
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of AR083541A1 publication Critical patent/AR083541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporciona un derivado de la vitamina D3, útil como agente terapéutico para la osteoporosis. Se proporciona un derivado de la vitamina D3 representado por la fórmula (1), o un solvato medicinalmente aceptable de él, en donde R1 representa un átomo de hidrógeno, un grupo alquilo C1-6, un grupo alquilcarboniloxialquilo donde cada alquilo tiene C1-6, o un grupo arilcarboniloxialquilo donde el arilo tiene C6-10 y el alquilo tiene C1-6; R2 representa un átomo de hidrógeno o un grupo alquilo C1-6 o, junto con el otro R2 y el átomo de carbono al cual están unidos, puede formar un grupo alquilo cíclico que tiene C3-6; R3 representa un grupo alquilo C1-6 o, junto con el otro R3 y el átomo de carbono al cual están unidos, puede formar un grupo alquilo cíclico C3-6; X representa un átomo de oxígeno o un grupo metileno; y n representa un entero de 1 ó 2.
ARP110103926A 2010-10-25 2011-10-24 Derivado de 23-ino-vitamina d AR083541A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010238524 2010-10-25

Publications (1)

Publication Number Publication Date
AR083541A1 true AR083541A1 (es) 2013-03-06

Family

ID=45993776

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103926A AR083541A1 (es) 2010-10-25 2011-10-24 Derivado de 23-ino-vitamina d

Country Status (21)

Country Link
US (2) US9006220B2 (es)
EP (1) EP2634171B8 (es)
JP (1) JP5738307B2 (es)
KR (1) KR101853518B1 (es)
CN (2) CN103180293B (es)
AR (1) AR083541A1 (es)
AU (1) AU2011321624B2 (es)
BR (1) BR112013009647A2 (es)
CA (1) CA2815501C (es)
DK (1) DK2634171T3 (es)
ES (1) ES2541719T3 (es)
HU (1) HUE025554T2 (es)
IL (1) IL225630A0 (es)
MX (1) MX347126B (es)
PH (1) PH12013500823A1 (es)
PL (1) PL2634171T3 (es)
PT (1) PT2634171E (es)
RU (1) RU2558362C2 (es)
SG (1) SG189427A1 (es)
TW (1) TWI503120B (es)
WO (1) WO2012057068A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201406380A (zh) * 2012-04-24 2014-02-16 Teijin Pharma Ltd 次發性副甲狀腺機能亢進症治療劑
JP2020143008A (ja) * 2019-03-05 2020-09-10 達也 楠堂 新規褐色脂肪細胞分化誘導剤
CN114681467B (zh) * 2022-03-30 2024-03-12 南通华山药业有限公司 一种阿法骨化醇杂环酯类衍生物在制备抗肿瘤药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804502A (en) * 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
GB9017890D0 (en) 1990-08-15 1990-09-26 Leo Pharm Prod Ltd Chemical compounds i
AU666563B2 (en) * 1992-08-07 1996-02-15 Wisconsin Alumni Research Foundation Preparation of 19-nor-vitamin D compounds
SG70010A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Fluorinated vitamin d3 analogs
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
GB9611603D0 (en) * 1996-06-04 1996-08-07 Leo Pharm Prod Ltd Chemical compounds
KR100593238B1 (ko) 1997-06-25 2006-06-26 데이진 가부시키가이샤 비타민 ｄ3 유도체 및 이로부터 제조된 염증성 호흡기 질환 치료제
US6359152B2 (en) * 1997-07-21 2002-03-19 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
US6538145B2 (en) * 1998-02-24 2003-03-25 Chugai Seiyaku Kabushiki Kaisha 24-hydroxy vitamin D derivatives
DE69939106D1 (de) * 1998-02-24 2008-08-28 Chugai Pharmaceutical Co Ltd Verfahren zur Herstellung von ED-71
AU3167699A (en) * 1998-04-10 1999-11-01 Chugai Seiyaku Kabushiki Kaisha Vitamin d derivatives substituted at the 2beta-position
WO2001062723A1 (en) * 2000-02-28 2001-08-30 Chugai Seiyaku Kabushiki Kaisha VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2α-POSITION
AU2005289664A1 (en) * 2004-09-24 2006-04-06 Bioxell S.P.A. 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin D3 compounds and methods of use thereof
JP2009013154A (ja) * 2006-09-29 2009-01-22 Teijin Pharma Ltd ２−置換−１４−エピ−プレビタミンｄ３誘導体

Also Published As

Publication number Publication date
KR101853518B1 (ko) 2018-04-30
HUE025554T2 (en) 2016-02-29
SG189427A1 (en) 2013-05-31
CN104829510A (zh) 2015-08-12
US9006220B2 (en) 2015-04-14
DK2634171T3 (en) 2015-07-13
HK1211281A1 (zh) 2016-05-20
AU2011321624A8 (en) 2013-09-12
AU2011321624B2 (en) 2015-03-26
MX2013004389A (es) 2013-05-22
PL2634171T3 (pl) 2015-12-31
RU2558362C2 (ru) 2015-08-10
JPWO2012057068A1 (ja) 2014-05-12
JP5738307B2 (ja) 2015-06-24
MX347126B (es) 2017-04-17
CN103180293A (zh) 2013-06-26
PT2634171E (pt) 2015-09-16
IL225630A0 (en) 2013-06-27
PH12013500823A1 (en) 2019-03-22
KR20140001874A (ko) 2014-01-07
CA2815501A1 (en) 2012-05-03
CN103180293B (zh) 2015-06-17
HK1184133A1 (en) 2014-01-17
US20150148552A1 (en) 2015-05-28
EP2634171A1 (en) 2013-09-04
US20130210781A1 (en) 2013-08-15
CA2815501C (en) 2018-10-16
ES2541719T3 (es) 2015-07-24
EP2634171B8 (en) 2016-01-13
CN104829510B (zh) 2016-05-04
RU2013124033A (ru) 2014-12-10
WO2012057068A1 (ja) 2012-05-03
TW201223531A (en) 2012-06-16
EP2634171B1 (en) 2015-07-01
EP2634171A4 (en) 2013-11-13
AU2011321624A1 (en) 2013-05-09
US9079843B2 (en) 2015-07-14
BR112013009647A2 (pt) 2016-07-12
TWI503120B (zh) 2015-10-11

Similar Documents

Publication Publication Date Title
MX2020010330A (es) Proceso para preparar un compuesto antiviral de formula i.
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
PE20160090A1 (es) Metodos para sintetizar un analogo de la prostaciclina
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
CO6400139A2 (es) Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica
BR112014018032A2 (pt) método para produzir uma composição
MX2012006994A (es) Agente antiplaquetas novedoso.
BR112014028801A2 (pt) ensaios com base em célula interrogatória para identificar marcadores de toxicidade induzida por fármaco
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
IN2014MN01521A (es)
PE20140976A1 (es) Inhibidores de benzodioxano de la producion de leucotrieno
BR112013024223A2 (pt) composto de poliéter, agente de cura usando o composto de poliéter, e método de produção do composto de poliéter
CO7111275A2 (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
AR075158A1 (es) Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR087274A1 (es) Derivados de amidas heterociclicas como antagonistas de receptores p2x7
MY171201A (en) New carbamate glycolipid and use thereof
ES2721623T3 (es) Procedimiento novedoso para la preparación de ceftarolina fosamil
CY1113914T1 (el) Νεα παραγωγα διυδροϊνδολονων, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
MX2013006811A (es) Compuestos, composiciones y articulos fotocromaticos.
PH12014502752A1 (en) Novel cyclic depsipeptide derivative and pest control agent compromising same
CO6400145A2 (es) Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica
AR083541A1 (es) Derivado de 23-ino-vitamina d
BR112017007784A2 (pt) aperfeiçoamentos em ou relacionados a compostos orgânicos
AR075251A1 (es) Derivados de 6-(6-sustituido-triazolopiridazina-sulfanil)-5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles, metodo de preparacion e intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del cancer y otros trastorno hiperproliferativos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal